Anlon healthcare has received a regulatory disclosure from Neomile Asset Managers Pvt. Ltd. regarding the substantial sale of shares by its associated investment entities. The transaction represents a significant reduction in the asset manager's stake in the healthcare company through open market operations.

Transaction Details

The disclosure reveals that Neomile Growth Fund – Series I and Neomile Corporate Advisory Limited, acting as persons acting in concert (PAC), disposed of shares in Anlon Healthcare between November 6, 2025, and January 9, 2026. The following table summarizes the key transaction parameters:

Shareholding Changes

The sale resulted in a notable reduction in Neomile's collective stake in Anlon Healthcare. The shareholding pattern before and after the transaction shows:

The entities involved in the transaction maintained no encumbrances, warrants, or convertible securities before or after the sale. All holdings were in the form of ordinary shares carrying voting rights.

Regulatory Compliance

The disclosure was made in accordance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. Neomile Asset Managers submitted the required documentation to:

• National Stock Exchange of India Ltd. (NSE Scrip Code: AHCL)
• BSE Limited (BSE Scrip Code: 544497)
• Anlon Healthcare Limited directly

The disclosure was signed by CA Rashesh Shah, Director of Neomile Asset Managers Pvt. Ltd., on January 9, 2026, from Mumbai.

Entity Information

The disclosure identified the key entities involved in the transaction:

Both entities confirmed they do not belong to the promoter or promoter group of Anlon Healthcare Limited. The transaction represents a strategic portfolio adjustment by the asset management firm and its associated investment vehicles in the healthcare sector company.

Anlon Healthcare Limited has successfully completed its strategic acquisition of Apiqo Organics Private Limited, marking a significant milestone in the company's expansion strategy. The pharmaceutical company announced the completion of acquiring a 67.48% equity stake in the target company on January 9, 2026.

Acquisition Details

The acquisition was executed in accordance with the Share Purchase Agreement (SPA) dated December 2, 2025, which was previously disclosed to the stock exchanges. Following the completion of this transaction, Apiqo Organics Private Limited has become a subsidiary of Anlon Healthcare Limited.

Regulatory Compliance

The investment and acquisition transaction has been structured in full compliance with applicable regulatory requirements. The company confirmed that the acquisition adheres to Section 179(3)(e) & (j) and all other applicable provisions of the Companies Act, 2013.

The disclosure was made pursuant to Regulation 30(7) read with Para A of Part A of Schedule III of the SEBI Listing Regulations. This follows the company's earlier intimation dated December 2, 2025, regarding the execution of the Share Purchase Agreement.

Corporate Structure Impact

With the completion of this acquisition, Anlon Healthcare has expanded its corporate structure through the addition of Apiqo Organics as a subsidiary. The target company was formerly known as M/s Apple Life Science, operating as a partnership firm before its transformation into a private limited company.

The transaction details, as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, were previously provided in the December 2, 2025 disclosure to ensure complete regulatory transparency.

Management Authorization

The acquisition completion was formally communicated to both BSE Limited and The National Stock Exchange of India Ltd by Managing Director Punitkumar Rasadia, who digitally signed the disclosure document on January 9, 2026. The communication ensures that all stakeholders and regulatory bodies are informed of this significant corporate development in accordance with listing obligations.